Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan

• Autors principals: Akiko Mizukami (Autor), Victor Preckler (Autor), Frederik Verelst (Autor), Taizo Matsuki (Autor), Yufan Ho (Autor), Daisuke Kurai (Autor), Daniel Molnar (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Objectives Older adults (OA) are at risk of morbidity and mortality from respiratory syncytial virus (RSV), a major cause of seasonal acute respiratory illness. The first RSV vaccine for OA (RSVPreF3 OA) was recently launched in Japan. With the already large and growing OA population in Japan, and l...